CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek poniżej 25 lat
- •Pierwszy przeszczep szpiku kostnego
- •Potwierdzony nowotwór krwi wymagający przeszczepu (białaczka, zespół mielodysplastyczny lub chłoniak)
- •Badania organów wewnętrznych i zakaźeń bez niepokojących wyników
- •Zgoda rodzica, opiekuna lub pacjenta (jeśli pełnoletni)
✗ Disqualifies
- •Brak bliskiego krewnego jako dawcy
- •Zaburzenia genetyczne wpływające na naprawę DNA
- •Pewne typy chłoniaków
- •Ciąża
Simplified criteria — AI translation
Trial details
- Maximum age
- 25 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Children's Hospital of Philadelphia
Philadelphia, United States
Trial contact
Megan Atkinson
Patricia Hankins, BSN, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.